Inhibitors for Cancer Stem Cells

Cancer Stem-Like Cells (CSCs) are a part of a theory that describes the process of tumorigenesis and resistance to traditional chemotherapy. CSCs constitute a small subset of cancer cells with the potential to self-renew and differentiate, thus triggering tumorigenesis.

Cancer Stem-Like Cells (CSCs)

Comparing CSCs and Normal Stem Cells

Various properties of CSCs are similar to that of normal stem cells (SCs). Both constitute only a very small proportion of the total number of cells, are multipotent, are predominantly quiescent, and have the ability to self-renew indefinitely. Moreover, CSCs and SCs have similar molecular signaling profiles like Notch, Wnt, Hedgehog, and so on.

But in contrast to normal SCs that differentiate into mature, healthy cell types, CSCs tend to differentiate into cancer cells and promote tumor growth and metastasis. Furthermore, CSCs have a role to play in the resistance of tumors to therapy as well as in the recurrence of the disease. Therefore, small molecule inhibitors of Cancer Stem Cells are appealing as pharmaceutical candidates for cancer therapy.

BioVision’s Cancer Stem Cell Inhibitors

BioVision takes pleasure in offering an extensive range of Cancer Stem Cell Inhibitors for Cancer Research. All products from BioVision have been tested well by scientists across the globe, with more and more citations in scientific publications.

Key Features

  • Cost-effective
  • Selective
  • High purity

BioVision Incorporated

BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.

BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Feb 21, 2020 at 9:30 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioVision Incorporated. (2020, February 21). Inhibitors for Cancer Stem Cells. News-Medical. Retrieved on September 22, 2020 from https://www.news-medical.net/whitepaper/20190801/Inhibitors-for-Cancer-Stem-Cells.aspx.

  • MLA

    BioVision Incorporated. "Inhibitors for Cancer Stem Cells". News-Medical. 22 September 2020. <https://www.news-medical.net/whitepaper/20190801/Inhibitors-for-Cancer-Stem-Cells.aspx>.

  • Chicago

    BioVision Incorporated. "Inhibitors for Cancer Stem Cells". News-Medical. https://www.news-medical.net/whitepaper/20190801/Inhibitors-for-Cancer-Stem-Cells.aspx. (accessed September 22, 2020).

  • Harvard

    BioVision Incorporated. 2020. Inhibitors for Cancer Stem Cells. News-Medical, viewed 22 September 2020, https://www.news-medical.net/whitepaper/20190801/Inhibitors-for-Cancer-Stem-Cells.aspx.

Other White Papers by this Supplier